Published in Clin Pharmacol Ther on March 31, 2010
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nucl Med Commun (2013) 2.12
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
PET imaging with ⁸⁹Zr: from radiochemistry to the clinic. Nucl Med Biol (2012) 1.74
Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma. J Nucl Med (2014) 1.52
Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging (2011) 1.50
PET tracers based on Zirconium-89. Curr Radiopharm (2011) 1.48
Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res (2011) 1.46
Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol (2012) 1.39
PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med (2012) 1.38
Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions. Mol Imaging (2011) 1.37
Quantitative imaging of disease signatures through radioactive decay signal conversion. Nat Med (2013) 1.33
Monoclonal antibodies in cancer therapy. Cancer Immun (2012) 1.31
Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol (2013) 1.18
Recent trends in antibody-based oncologic imaging. Cancer Lett (2011) 1.17
Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets. EJNMMI Res (2011) 1.16
Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW. Mol Pharm (2012) 1.14
ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW. Am J Transl Res (2012) 1.14
Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. J Nucl Med (2013) 1.14
Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). J Med Chem (2014) 1.13
Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging (2012) 1.12
Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med (2013) 1.12
Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs (2010) 1.09
MicroPET imaging of integrin αvβ3 expressing tumors using 89Zr-RGD peptides. Mol Imaging Biol (2011) 1.08
Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev (2012) 1.06
In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Nucleic Acid Ther (2011) 1.05
Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy. Curr Opin Oncol (2010) 1.04
Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo. Proc Natl Acad Sci U S A (2014) 1.04
Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells. Proc Natl Acad Sci U S A (2014) 1.03
(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res (2015) 1.01
Leptomeningeal metastases in breast cancer. Am J Cancer Res (2013) 1.00
Breast cancer brain metastases: the last frontier. Exp Hematol Oncol (2015) 0.99
89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors. Pharmaceuticals (Basel) (2012) 0.98
Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with (89)Zr(4+): comparison with desferrioxamine-B. Dalton Trans (2015) 0.97
VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. Oncotarget (2016) 0.96
An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Cancer Res (2015) 0.96
Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging. Nat Protoc (2013) 0.96
PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol (2012) 0.95
Future directions for the early detection of recurrent breast cancer. J Cancer (2014) 0.95
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat (2012) 0.94
Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model. Bioconjug Chem (2012) 0.93
Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist (2015) 0.92
89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget (2015) 0.91
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials? Front Pharmacol (2016) 0.91
Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics. Pharmacol Rev (2013) 0.89
(89)Zr-labeled paramagnetic octreotide-liposomes for PET-MR imaging of cancer. Pharm Res (2012) 0.89
Multimodality and nanoparticles in medical imaging. Dalton Trans (2011) 0.89
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT. Theranostics (2016) 0.89
A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. EJNMMI Res (2011) 0.88
Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET. PLoS One (2013) 0.88
Positron emission tomography image-guided drug delivery: current status and future perspectives. Mol Pharm (2014) 0.88
Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts. Mol Pharm (2014) 0.87
Tissue distribution studies of protein therapeutics using molecular probes: molecular imaging. AAPS J (2012) 0.87
Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro Oncol (2015) 0.87
p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET. Bioconjug Chem (2015) 0.87
Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol (2015) 0.87
Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat Rev Clin Oncol (2012) 0.86
Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor. Mol Imaging (2013) 0.86
How Does the Patient Benefit from Clinical PET? Theranostics (2012) 0.86
The use of (18)F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer. ACS Cent Sci (2015) 0.86
New strategy for monitoring targeted therapy: molecular imaging. Int J Nanomedicine (2013) 0.85
Novel (89)Zr cell labeling approach for PET-based cell trafficking studies. EJNMMI Res (2015) 0.85
ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116. MAbs (2014) 0.84
Antibody-based imaging strategies for cancer. Cancer Metastasis Rev (2014) 0.84
Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients. Biomed Res Int (2014) 0.84
Molecular imaging probes for diagnosis and therapy evaluation of breast cancer. Int J Biomed Imaging (2013) 0.84
Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nucl Med Mol Imaging (2010) 0.84
Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res (2010) 0.84
Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions. Radiochim Acta (2012) 0.84
Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging. Oncotarget (2015) 0.83
Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions. Cancer Lett (2013) 0.83
Mapping biological behaviors by application of longer-lived positron emitting radionuclides. Adv Drug Deliv Rev (2012) 0.83
Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. Breast Cancer Res Treat (2013) 0.83
Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. J Nucl Med (2016) 0.83
Macrocycle-Based Hydroxamate Ligands for Complexation and Immunoconjugation of (89)Zirconium for Positron Emission Tomography (PET) Imaging. Chempluschem (2016) 0.82
Pilot study of (89)Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer. EJNMMI Res (2014) 0.82
Tumor immunotargeting using innovative radionuclides. Int J Mol Sci (2015) 0.82
EATRIS, a European initiative to boost translational biomedical research. Am J Nucl Med Mol Imaging (2013) 0.82
Enzyme-Mediated Modification of Single-Domain Antibodies for Imaging Modalities with Different Characteristics. Angew Chem Int Ed Engl (2015) 0.81
64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One (2014) 0.81
Cyclotron Production of High-Specific Activity 55Co and In Vivo Evaluation of the Stability of 55Co Metal-Chelate-Peptide Complexes. Mol Imaging (2015) 0.81
Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol (2016) 0.81
Impact of expression system on the function of the C6.5 diabody PET radiotracer. Tumour Biol (2012) 0.81
Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope. Radiology (2015) 0.81
Targeted Therapies for Brain Metastases from Breast Cancer. Int J Mol Sci (2016) 0.80
Imaging metabolic heterogeneity in cancer. Mol Cancer (2016) 0.80
Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies. MAbs (2013) 0.80
The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis. Br J Radiol (2014) 0.80
Use of a single hybrid imaging agent for integration of target validation with in vivo and ex vivo imaging of mouse tumor lesions resembling human DCIS. PLoS One (2013) 0.80
Immuno-PET for Clinical Theranostic Approaches. Int J Mol Sci (2016) 0.80
[(89)Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Mol Imaging Biol (2016) 0.79
Immuno-PET imaging of tumor endothelial marker 8 (TEM8). Mol Pharm (2014) 0.79
Treatment of early-stage HER2+ breast cancer-an evolving field. Ecancermedicalscience (2015) 0.79
Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging. Am J Nucl Med Mol Imaging (2016) 0.79
Molecular Imaging of Biomarkers in Breast Cancer. J Nucl Med (2016) 0.78
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. MAbs (2015) 0.78
Cancer stratification by molecular imaging. Int J Mol Sci (2015) 0.78
Management of solitary and multiple brain metastases from breast cancer. Indian J Med Paediatr Oncol (2015) 0.77
Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma. J Nucl Med (2014) 0.77
[Guideline 'Renal cell carcinoma']. Ned Tijdschr Geneeskd (2008) 2.89
Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A (1994) 2.52
No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol (2001) 2.31
Increased cancer risk after liver transplantation: a population-based study. J Hepatol (2001) 2.25
Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med (2000) 2.19
Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med (2001) 2.18
Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res (1993) 1.99
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol (2001) 1.92
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol (2000) 1.89
Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res (1993) 1.81
Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res (1987) 1.81
Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol (1992) 1.62
The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev (2004) 1.60
Subtotal cystectomy as a complication of infant hernia repair. Eur J Surg (1998) 1.58
Is sentinel node biopsy beneficial in melanoma patients? A report on 200 patients with cutaneous melanoma. Eur J Surg Oncol (2002) 1.54
Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med (2000) 1.52
The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. J Cell Biol (1995) 1.51
Sentinel node detection in patients with breast cancer: low-energy all-purpose collimator or medium-energy collimator? Clin Nucl Med (2004) 1.47
Combination therapy with cisplatin: modulation of activity and tumour sensitivity. Clin Oncol (R Coll Radiol) (1992) 1.43
Excessively high cell proliferation in sigmoid colon after an oral purge with anthraquinone glycosides. J Natl Cancer Inst (1995) 1.43
Diagnostic and therapeutic approach of systemic amyloidosis. Neth J Med (2004) 1.43
Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity. Clin Cancer Res (2000) 1.42
5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. Cancer (1995) 1.40
Endodermal sinus tumor of the ovary during pregnancy: a case report. Am J Obstet Gynecol (1991) 1.40
[Good results with liver resection for colorectal liver metastases]. Ned Tijdschr Geneeskd (1995) 1.40
[Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients]. Ned Tijdschr Geneeskd (2005) 1.39
[AL-amyloidosis and its treatment by eliminating the precursor protein]. Ned Tijdschr Geneeskd (2007) 1.39
[Carboplatin in the treatment of ovarian carcinoma; as effective and less toxic in comparison with cisplatin]. Ned Tijdschr Geneeskd (1991) 1.38
Evaluation of 99mTc-MAMA-chrysamine G as an in vivo probe for amyloidosis. Amyloid (2001) 1.38
Intraoperative near-infrared fluorescence imaging for sentinel lymph node detection in vulvar cancer: first clinical results. Gynecol Oncol (2010) 1.38
The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev (2000) 1.37
Review article: anthranoid laxatives and their potential carcinogenic effects. Aliment Pharmacol Ther (1999) 1.34
Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res (1990) 1.33
Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer (2001) 1.28
Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res (2001) 1.28
Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol (1998) 1.28
Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int J Cancer (1999) 1.27
Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer (1992) 1.25
Molecular imaging of breast cancer. Breast (2009) 1.22
Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res (1992) 1.21
Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res (1988) 1.21
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood (1995) 1.19
Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: improved efficacy in photodynamic therapy. Cancer Res (2001) 1.19
ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol (1999) 1.17
Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood (1994) 1.16
P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res (1991) 1.16
Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J Natl Cancer Inst (1989) 1.16
Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma. J Cancer Res Clin Oncol (1989) 1.16
Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res (1992) 1.14
Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy. Cancer Res (1999) 1.14
Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Br J Cancer (1996) 1.12
[Efficient and improved diagnosis of osteoporosis by simultaneous bone density measurement and spinal morphometry]. Ned Tijdschr Geneeskd (2008) 1.12
Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer (2005) 1.12
Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol (1995) 1.10
High performance liquid chromatographic profiling of tryptophan and related indoles in body fluids and tissues of carcinoid patients. Clin Chim Acta (1993) 1.09
Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. Eur J Nucl Med Mol Imaging (2008) 1.08
Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J Pharmacol Exp Ther (2000) 1.08
Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Cancer Res (1988) 1.08
Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype. Proc Natl Acad Sci U S A (1992) 1.08
Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer. Br J Cancer (2000) 1.07
Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology (1999) 1.05
Combined in vitro modulation of adriamycin resistance. Int J Cancer (1991) 1.04
Clinical chemistry of serotonin and metabolites. J Chromatogr B Biomed Sci Appl (2000) 1.03
Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet (1991) 1.02
Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clin Cancer Res (1998) 1.02
Ophthalmic toxicity following paclitaxel infusion. Ann Oncol (1997) 1.00
Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. Int J Cancer (1995) 1.00
Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Endoscopy (2008) 1.00
Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol (1999) 1.00
Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer (1996) 1.00
Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med (1992) 1.00
Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem (2000) 0.99
A 22-kd surface antigen detected by monoclonal antibody E 48 is exclusively expressed in stratified squamous and transitional epithelia. Am J Pathol (1990) 0.99
Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma. Br J Cancer (1990) 0.99
Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res (1996) 0.99
Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics. J Nucl Med (1996) 0.98
Development and validation of a patient-tailored dose regime in myocardial perfusion imaging using CZT-SPECT. J Nucl Cardiol (2014) 0.97
Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res (1999) 0.97
Effects of supplemental dietary calcium on quantitative and qualitative fecal fat excretion in man. Ann Nutr Metab (1994) 0.96
High-dose etoposide for refractory malignancies: a phase I study. Cancer Treat Rep (1984) 0.96
Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncology (1996) 0.96
Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol (2004) 0.96
Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear. J Clin Oncol (1998) 0.96
A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res (1999) 0.96
High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. Cancer (1997) 0.96
Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN. J Nucl Med (2001) 0.96
Visualization of multidrug resistance in vivo. Eur J Nucl Med (1999) 0.96
A case of localized Castleman's disease with systemic involvement: treatment and pathogenetic aspects. Ann Hematol (1996) 0.95
cis-diamminedichloroplatinum(ii) resistance in vitro and in vivo in human embryonal carcinoma cells. Cancer Res (1993) 0.95
Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. Cancer Res (1991) 0.95
Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev (1999) 0.95
Functional results after treatment of hip fracture: a multicentre, prospective study in 215 patients. Eur J Surg (2000) 0.95
Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer. Int J Cancer (2001) 0.95
The interparietal hernia: a rare variant of an inguinal hernia. Eur J Surg (1997) 0.94
Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia (2001) 0.94